Third Rock Ventures launches SF firm with $38m Series A financing
MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease.
MyoKardia will be located in San Francisco and is the second company launched out of Third Rock’s West Coast office, a firm spokeswoman said.
“The last decade has been challenging for those pursuing novel therapeutics in the cardiovascular space, in part because most treatments target symptoms far downstream of the root cause,” Dr. Leslie Leinwand, a company cofounder, said in a statement. “MyoKardia’s approach addresses this challenge head on by employing genetics to more precisely define the disease and ‘who we want to treat,’ and by employing cutting-edge muscle biochemistry and a novel platform to determine ‘how we want to treat.’ Our initial targets are genetic cardiomyopathies, but this could very well be a novel and tractable therapeutic discovery approach to even larger diseases like heart failure.”
Other company cofounders include Christine Seidman, M.D., professor of medicine and genetics at Harvard Medical School and director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital, and Jonathan Seidman, professor of genetics at Harvard Medical School.Chris Reidy can be reached at firstname.lastname@example.org.